Nedosiran safety and efficacy in PH1: interim analysis of PHYOX3
Introduction - Primary hyperoxaluria (PH) is a rare genetic disorder of hepatic glyoxylate metabolism. Nedosiran is an RNA interference (RNAi) therapeutic that the US Food and Drug Administration has approved for treatment of PH1. PHYOX3 is a trial evaluating monthly nedosiran in patients with PH. -...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 2024
|
| In: |
Kidney international. Reports
Year: 2024, Jahrgang: 9, Heft: 5, Pages: 1387-1396 |
| ISSN: | 2468-0249 |
| DOI: | 10.1016/j.ekir.2024.02.1439 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ekir.2024.02.1439 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2468024924015298 
|
| Verfasserangaben: | Jaap Groothoff, Anne-Laure Sellier-Leclerc, Lisa Deesker, Justine Bacchetta, Gesa Schalk, Burkhard Tönshoff, Graham Lipkin, Sandrine Lemoine, Thomas Bowman, Jing Zhou and Bernd Hoppe |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1915385407 | ||
| 003 | DE-627 | ||
| 005 | 20250716223801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ekir.2024.02.1439 |2 doi | |
| 035 | |a (DE-627)1915385407 | ||
| 035 | |a (DE-599)KXP1915385407 | ||
| 035 | |a (OCoLC)1528017268 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Groothoff, Jaap |e VerfasserIn |0 (DE-588)1354063686 |0 (DE-627)1915386187 |4 aut | |
| 245 | 1 | 0 | |a Nedosiran safety and efficacy in PH1 |b interim analysis of PHYOX3 |c Jaap Groothoff, Anne-Laure Sellier-Leclerc, Lisa Deesker, Justine Bacchetta, Gesa Schalk, Burkhard Tönshoff, Graham Lipkin, Sandrine Lemoine, Thomas Bowman, Jing Zhou and Bernd Hoppe |
| 264 | 1 | |c May 2024 | |
| 300 | |b Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.01.2025 | ||
| 520 | |a Introduction - Primary hyperoxaluria (PH) is a rare genetic disorder of hepatic glyoxylate metabolism. Nedosiran is an RNA interference (RNAi) therapeutic that the US Food and Drug Administration has approved for treatment of PH1. PHYOX3 is a trial evaluating monthly nedosiran in patients with PH. - Methods - In this PHYOX3 interim analysis, participants with PH1 who continued from a single-dose nedosiran trial (PHYOX1), with no previous kidney or liver transplantation, dialysis, or evidence of systemic oxalosis were eligible. The safety and efficacy of once-monthly nedosiran was assessed over 30 months. - Results - Thirteen participants completed PHYOX1 and continued into PHYOX3. At baseline, the mean (SD) and median (range) age was 24.2 (6.6) years and 23.0 (14-39) years, respectively; 53.8% were female and 61.5% were White. Mean estimated glomerular filtration rate (eGFR) remained stable (62-84.2 mL/min per 1.73 m2) to month 30. Mean 24-hour urinary oxalate (Uox) excretion showed a sustained reduction from baseline of ≥60% at every visit (months 2-30). From month 2, at least 10 of 13 (76.9%) participants achieved normal (<0.46 mmol/24h; upper limit of assay-normal [ULN]) or near-normal (≥0.46 to <0.60 mmol/24h; ≥ULN to <1.3 × ULN) 24-hour Uox excretion. All participants experienced ≥1 adverse event (AE), mostly mild or moderate in severity (primarily, injection site events). Three serious, not treatment-related AEs were reported; there were no deaths or study discontinuations due to AEs. - Conclusion - Nedosiran was well-tolerated in patients with PH1, and treatment resulted in a sustained, substantial reduction in Uox excretion for at least 30 months in this long-term study. No safety signals have been identified to date. The PHYOX3 study is ongoing. | ||
| 650 | 4 | |a glyoxylate metabolism | |
| 650 | 4 | |a nedosiran | |
| 650 | 4 | |a primary hyperoxaluria type 1 | |
| 650 | 4 | |a RNAi therapy | |
| 650 | 4 | |a safety/efficacy | |
| 650 | 4 | |a urinary oxalate excretion | |
| 700 | 1 | |a Sellier-Leclerc, Anne-Laure |e VerfasserIn |4 aut | |
| 700 | 1 | |a Deesker, Lisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bacchetta, Justine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schalk, Gesa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tönshoff, Burkhard |e VerfasserIn |0 (DE-588)1032445823 |0 (DE-627)738463493 |0 (DE-576)173494196 |4 aut | |
| 700 | 1 | |a Lipkin, Graham |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lemoine, Sandrine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bowman, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zhou, Jing |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoppe, Bernd |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international. Reports |d Amsterdam : Elsevier, 2016 |g 9(2024), 5 vom: Mai, Seite 1387-1396 |h Online-Ressource |w (DE-627)881695580 |w (DE-600)2887223-X |w (DE-576)485146266 |x 2468-0249 |7 nnas |a Nedosiran safety and efficacy in PH1 interim analysis of PHYOX3 |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:5 |g month:05 |g pages:1387-1396 |g extent:10 |a Nedosiran safety and efficacy in PH1 interim analysis of PHYOX3 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ekir.2024.02.1439 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2468024924015298 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250122 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1032445823 |a Tönshoff, Burkhard |m 1032445823:Tönshoff, Burkhard |d 910000 |d 910500 |d 50000 |e 910000PT1032445823 |e 910500PT1032445823 |e 50000PT1032445823 |k 0/910000/ |k 1/910000/910500/ |k 0/50000/ |p 6 | ||
| 999 | |a KXP-PPN1915385407 |e 4655063181 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"May 2024","dateIssuedKey":"2024"}],"id":{"eki":["1915385407"],"doi":["10.1016/j.ekir.2024.02.1439"]},"name":{"displayForm":["Jaap Groothoff, Anne-Laure Sellier-Leclerc, Lisa Deesker, Justine Bacchetta, Gesa Schalk, Burkhard Tönshoff, Graham Lipkin, Sandrine Lemoine, Thomas Bowman, Jing Zhou and Bernd Hoppe"]},"physDesc":[{"extent":"10 S.","noteIll":"Diagramme"}],"relHost":[{"part":{"extent":"10","volume":"9","text":"9(2024), 5 vom: Mai, Seite 1387-1396","pages":"1387-1396","issue":"5","year":"2024"},"titleAlt":[{"title":"KI reports"},{"title":"Kidney international reports"}],"pubHistory":["Volume 1, issue 1 (May 2016)-"],"recId":"881695580","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Nedosiran safety and efficacy in PH1 interim analysis of PHYOX3Kidney international. Reports","note":["Gesehen am 23.06.20"],"title":[{"title_sort":"Kidney international","title":"Kidney international","partname":"Reports"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2468-0249"],"zdb":["2887223-X"],"eki":["881695580"]},"origin":[{"publisherPlace":"Amsterdam","dateIssuedDisp":"[2016]-","publisher":"Elsevier"}]}],"title":[{"title_sort":"Nedosiran safety and efficacy in PH1","subtitle":"interim analysis of PHYOX3","title":"Nedosiran safety and efficacy in PH1"}],"person":[{"given":"Jaap","family":"Groothoff","role":"aut","roleDisplay":"VerfasserIn","display":"Groothoff, Jaap"},{"roleDisplay":"VerfasserIn","display":"Sellier-Leclerc, Anne-Laure","role":"aut","family":"Sellier-Leclerc","given":"Anne-Laure"},{"given":"Lisa","family":"Deesker","role":"aut","roleDisplay":"VerfasserIn","display":"Deesker, Lisa"},{"given":"Justine","family":"Bacchetta","role":"aut","display":"Bacchetta, Justine","roleDisplay":"VerfasserIn"},{"family":"Schalk","given":"Gesa","display":"Schalk, Gesa","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Tönshoff, Burkhard","role":"aut","family":"Tönshoff","given":"Burkhard"},{"family":"Lipkin","given":"Graham","roleDisplay":"VerfasserIn","display":"Lipkin, Graham","role":"aut"},{"given":"Sandrine","family":"Lemoine","role":"aut","display":"Lemoine, Sandrine","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Bowman, Thomas","role":"aut","family":"Bowman","given":"Thomas"},{"given":"Jing","family":"Zhou","role":"aut","display":"Zhou, Jing","roleDisplay":"VerfasserIn"},{"given":"Bernd","family":"Hoppe","role":"aut","roleDisplay":"VerfasserIn","display":"Hoppe, Bernd"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 22.01.2025"],"language":["eng"],"recId":"1915385407"} | ||
| SRT | |a GROOTHOFFJNEDOSIRANS2024 | ||